| Not Yet Recruiting | Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy NCT06131632 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Active Not Recruiting | Onvansertib + Paclitaxel In TNBC NCT05383196 | Antonio Giordano, MD | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Tra NCT05415215 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Refining Local-Regional Therapy for IBC NCT04636710 | Dana-Farber Cancer Institute | N/A |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Recruiting | Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer NCT04030507 | Brigham and Women's Hospital | N/A |
| Active Not Recruiting | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer NCT03515798 | Institut Paoli-Calmettes | Phase 2 |
| Completed | Denosumab as an add-on Neoadjuvant Treatment (GeparX) NCT02682693 | GBG Forschungs GmbH | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cance NCT02623972 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treat NCT02125344 | GBG Forschungs GmbH | Phase 3 |
| Terminated | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer NCT01938833 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Unknown | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Respo NCT02879513 | RenJi Hospital | Phase 3 |
| Active Not Recruiting | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients NCT02221999 | RenJi Hospital | Phase 2 / Phase 3 |
| Completed | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer NCT02199418 | RenJi Hospital | Phase 2 |
| Completed | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast NCT01583426 | GBG Forschungs GmbH | Phase 3 |
| Active Not Recruiting | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients Wit NCT01525966 | City of Hope Medical Center | Phase 2 |
| Completed | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer NCT01426880 | GBG Forschungs GmbH | Phase 2 / Phase 3 |
| Unknown | Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer NCT01880385 | Association Tunisienne de lutte Contre le Cancer | Phase 1 |
| Completed | Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer NCT01417286 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | MUC1 Vaccine for Triple-negative Breast Cancer NCT00986609 | Joseph Baar, MD, PhD | EARLY_Phase 1 |
| Unknown | Dose-escalation Study of Oral CX-4945 NCT00891280 | Cylene Pharmaceuticals | Phase 1 |
| Completed | Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patie NCT00513695 | University of Washington | Phase 2 |
| Completed | Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia NCT00344071 | National Cancer Institute (NCI) | — |
| Completed | Establishing an Inflammatory Breast Cancer Registry NCT00340158 | National Cancer Institute (NCI) | — |
| Completed | Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer NCT00049114 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treati NCT00016276 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer NCT02324088 | UNICANCER | Phase 3 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in NCT00003199 | Fred Hutchinson Cancer Center | Phase 2 |